Cargando…
Assessing deterioration using impairment and functional outcome measures in chronic inflammatory demyelinating polyneuropathy: A post‐hoc analysis of the immunoglobulin overtreatment in CIDP trial
It is unclear whether frequently used cutoff values for outcome measures defining minimal clinically important differences (MCIDs) can accurately identify meaningful deterioration in chronic inflammatory demyelinating polyneuropathy (CIDP). We used data from the immunoglobulin overtreatment in CIDP...
Autores principales: | van Veen, Robin, Wieske, Luuk, Lucke, Ilse, Adrichem, Max E., Merkies, Ingemar S. J., van Schaik, Ivo N., Eftimov, Filip |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321849/ https://www.ncbi.nlm.nih.gov/pubmed/35507446 http://dx.doi.org/10.1111/jns.12497 |
Ejemplares similares
-
Deterioration after corticosteroids in CIDP may be associated with pure focal demyelination pattern
por: Eftimov, Filip, et al.
Publicado: (2014) -
Combined intravenous immunoglobulin and methylprednisolone as induction treatment in chronic inflammatory demyelinating polyneuropathy (OPTIC protocol): a prospective pilot study
por: Adrichem, M. E., et al.
Publicado: (2019) -
Withdrawal of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy
por: Adrichem, Max E., et al.
Publicado: (2022) -
Clinical outcome of CIDP one year after start of treatment: a prospective cohort study
por: Bus, S. R. M., et al.
Publicado: (2021) -
Loss of Schwann cell plasticity in chronic inflammatory demyelinating polyneuropathy (CIDP)
por: Joshi, Abhijeet R., et al.
Publicado: (2016)